Pllans−II: Unveiling the action mechanism of a promising chemotherapeutic agent targeting cervical cancer cell adhesion and survival pathways

Despite advances in chemotherapeutic drugs used against cervical cancer, available chemotherapy treatments adversely affect the patient’s quality of life. For this reason, new molecules from natural sources with antitumor potential and few side effects are required. In previous research, Pllans-II, a phospholipase A2 type-Asp49 from Porthidium lansbergii lansbergii snake venom, has shown selective attack against the HeLa and Ca Ski cervical cancer cell lines. This work suggests that the cytotoxic effect generated by Pllans-II on HeLa cells is triggered without affecting the integrity of the cytoplasmic membrane or depolarizing the mitochondrial membranes. The results allow us to establish that cell death in HeLa is related to the junction blockage between a5B1 integrins and fibronectin of the extracellular matrix. Pllans-II reduces the cells’ ability of adhesion and affects survival and proliferation pathways mediated by intracellular communication with the external environment. Our findings confirmed Pllans-II as a potential prototype for developing a selective chemotherapeutic drug against cervical cancer

• Autores: Montoya-Gómez, Alejandro; Tonello, Fiorella; Spolaore, Barbara; Massimino, Maria Lina; Montealegre-Sánchez, Leonel; Castillo, Andrés; Rivera Franco, Nelson; Sevilla-Sánchez, María José; Solano-Redondo, Luis Manuel; Mosquera-Escudero, Mildrey; Jiménez-Charris, Eliécer; Montealegre Sánchez, Leonel Ives
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2023
• Institución: Universidad Autónoma de Occidente
• Repositorio: RED: Repositorio Educativo Digital UAO
• Idioma: eng
• OAI Identifier: oai:red.uao.edu.co:10614/15905
• Acceso en línea: https://hdl.handle.net/10614/15905; https://doi.org/10.3390/cells12232715; https://red.uao.edu.co/
• Palabra clave: Snake venom; Phospholipase A2; Bioprospecting; Antitumor potential; Transcriptomic analysis; Membrane receptor target
• Rights: openAccess
• License: Derechos reservados - MDPI, 2023